A Clinical Study of Precision Chemoablation for Hypertrophic Obstructive Cardiomyopathy Without Large Interventricular Septal Branches.

Objective: This study aims to evaluate the clinical efficacy and safety of ultrasound-guided percutaneous septal precision chemical ablation in the treatment of hypertrophic obstructive cardiomyopathy (HOCM).

Methods: From December 2020 to July 2024, 27 patients with HOCM without large target septal branches (diffuse multiple branches, all less than 1 mm in diameter) were enrolled and underwent ultrasound-guided percutaneous septal chemical ablation. Intraoperative left ventricular outflow tract gradient (LVOTG), postoperative cardiac troponin I (cTnI), complications, and changes in the 36-Item Short Form Survey (SF-36) score, New York Heart Association (NYHA) functional classification and echocardiography parameters in 1 year post-PTSMA were monitored and analyzed.